Enodia: Degrading secreted proteins before maturation

Enodia is developing a targeted protein degradation platform centered on SEC61, the translocon through which newly synthesized proteins destined for secretion or the cell surface enter the endoplasmic reticulum.

By selectively blocking SEC61, the Paris-based company aims to prevent disease-driving proteins from reaching their destinations, instead diverting them to cytosolic degradation via the proteasome...